Does the media favor ADMA or ANIP?

In the previous week, ANI Pharmaceuticals had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 4 mentions for ADMA Biologics. ANI Pharmaceuticals' average media sentiment score of 0.89 beat ADMA Biologics' score of 0.76 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ANIP or LNTH?

Lantheus has higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ANI Pharmaceuticals $978.38M 1.70 $78.34M $4.64 15.58 Lantheus $1.54B 4.23 $233.56M $4.14 24.15

Does the media prefer ANIP or LNTH?

In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 7 articles in the media. ANI Pharmaceuticals' average media sentiment score of 0.89 beat Lantheus' score of 0.54 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BLTE or ANIP?

In the previous week, ANI Pharmaceuticals had 1 more articles in the media than Belite Bio. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 6 mentions for Belite Bio. ANI Pharmaceuticals' average media sentiment score of 0.89 beat Belite Bio's score of 0.48 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ANI Pharmaceuticals (ANIP) Competitors

$72.57 +0.29 (+0.40%)

As of 09:48 AM Eastern

Compare

ANIP vs. ADMA, ANVS, LNTH, AMRX, and BLTE

Should you buy ANI Pharmaceuticals stock or one of its competitors? ANI Pharmaceuticals's main competitors and comparable companies include ADMA Biologics (ADMA), Annovis Bio (ANVS), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), and Belite Bio (BLTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does ANI Pharmaceuticals compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

ADMA Biologics has a net margin of 32.98% compared to ANI Pharmaceuticals' net margin of 11.07%. ADMA Biologics' return on equity of 40.17% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

ADMA Biologics currently has a consensus target price of $18.67, suggesting a potential upside of 73.97%. ANI Pharmaceuticals has a consensus target price of $99.60, suggesting a potential upside of 37.80%. Given ADMA Biologics' stronger consensus rating and higher probable upside, equities analysts plainly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ADMA Biologics has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

In the previous week, ANI Pharmaceuticals had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 4 mentions for ADMA Biologics. ANI Pharmaceuticals' average media sentiment score of 0.89 beat ADMA Biologics' score of 0.76 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has higher earnings, but lower revenue than ANI Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.71	$146.93M	$0.70	15.33
ANI Pharmaceuticals	$978.38M	1.70	$78.34M	$4.64	15.58

Summary

ADMA Biologics beats ANI Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

ANI Pharmaceuticals has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
ANI Pharmaceuticals	$978.38M	1.70	$78.34M	$4.64	15.58

In the previous week, ANI Pharmaceuticals had 7 more articles in the media than Annovis Bio. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 0 mentions for Annovis Bio. ANI Pharmaceuticals' average media sentiment score of 0.89 beat Annovis Bio's score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Annovis Bio	Neutral
ANI Pharmaceuticals	Positive

Annovis Bio presently has a consensus price target of $12.00, suggesting a potential upside of 1,035.29%. ANI Pharmaceuticals has a consensus price target of $99.60, suggesting a potential upside of 37.80%. Given Annovis Bio's higher possible upside, equities research analysts clearly believe Annovis Bio is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

Annovis Bio has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 15.9% of Annovis Bio shares are held by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ANI Pharmaceuticals has a net margin of 11.07% compared to Annovis Bio's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

Summary

ANI Pharmaceuticals beats Annovis Bio on 12 of the 15 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Lantheus?

ANI Pharmaceuticals (NASDAQ:ANIP) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 7 articles in the media. ANI Pharmaceuticals' average media sentiment score of 0.89 beat Lantheus' score of 0.54 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ANI Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

ANI Pharmaceuticals currently has a consensus target price of $99.60, suggesting a potential upside of 37.80%. Lantheus has a consensus target price of $107.44, suggesting a potential upside of 7.46%. Given ANI Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe ANI Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Lantheus	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21

Lantheus has a net margin of 17.69% compared to ANI Pharmaceuticals' net margin of 11.07%. Lantheus' return on equity of 28.10% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Lantheus	17.69%	28.10%	14.35%

Lantheus has higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$978.38M	1.70	$78.34M	$4.64	15.58
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.15

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Lantheus beats ANI Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

ANI Pharmaceuticals has lower revenue, but higher earnings than Amneal Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	2.04	$72.06M	$0.49	39.29
ANI Pharmaceuticals	$978.38M	1.70	$78.34M	$4.64	15.58

In the previous week, ANI Pharmaceuticals had 6 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 1 mentions for Amneal Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.89 beat Amneal Pharmaceuticals' score of 0.16 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Amneal Pharmaceuticals	Neutral
ANI Pharmaceuticals	Positive

Amneal Pharmaceuticals has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Amneal Pharmaceuticals currently has a consensus price target of $21.00, suggesting a potential upside of 9.09%. ANI Pharmaceuticals has a consensus price target of $99.60, suggesting a potential upside of 37.80%. Given ANI Pharmaceuticals' higher probable upside, analysts clearly believe ANI Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ANI Pharmaceuticals has a net margin of 11.07% compared to Amneal Pharmaceuticals' net margin of 5.05%. ANI Pharmaceuticals' return on equity of 27.37% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

Summary

ANI Pharmaceuticals beats Amneal Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does ANI Pharmaceuticals compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and ANI Pharmaceuticals (NASDAQ:ANIP) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

ANI Pharmaceuticals has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
ANI Pharmaceuticals	$978.38M	1.70	$78.34M	$4.64	15.58

ANI Pharmaceuticals has a net margin of 11.07% compared to Belite Bio's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

In the previous week, ANI Pharmaceuticals had 1 more articles in the media than Belite Bio. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 6 mentions for Belite Bio. ANI Pharmaceuticals' average media sentiment score of 0.89 beat Belite Bio's score of 0.48 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ANI Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio presently has a consensus target price of $218.73, suggesting a potential upside of 43.31%. ANI Pharmaceuticals has a consensus target price of $99.60, suggesting a potential upside of 37.80%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts clearly believe Belite Bio is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

ANI Pharmaceuticals beats Belite Bio on 11 of the 15 factors compared between the two stocks.

Get ANI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIP vs. The Competition

Export

Metric	ANI Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.67B	$12.43B	$7.31B	$12.93B
Dividend Yield	N/A	2.62%	2.51%	19.61%
P/E Ratio	15.64	670.72	217.88	21.17
Price / Sales	1.70	933.45	624.39	104.67
Price / Cash	7.06	83.43	76.19	51.56
Price / Book	3.02	9.28	10.47	6.01
Net Income	$78.34M	$2.84B	$3.50B	$380.68M
7 Day Performance	-1.79%	-3.81%	-3.34%	-3.16%
1 Month Performance	-1.39%	-7.00%	-6.60%	-5.20%
1 Year Performance	-21.08%	-4.65%	2.68%	-4.08%

ANI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIP ANI Pharmaceuticals	4.1814 of 5 stars	$72.57 +0.4%	$99.60 +37.2%	-19.8%	$1.67B	$978.38M	15.64	970
ADMA ADMA Biologics	3.7475 of 5 stars	$10.11 +4.0%	$18.67 +84.6%	-28.9%	$2.18B	$510.17M	14.44	647	News Coverage Gap Up
ANVS Annovis Bio	1.7613 of 5 stars	$1.19 +0.4%	$12.00 +912.7%	-41.8%	$50.36M	N/A	N/A	7
LNTH Lantheus	3.6937 of 5 stars	$100.19 +0.2%	$108.11 +7.9%	+76.9%	$6.52B	$1.54B	24.20	1,193	Analyst Forecast
AMRX Amneal Pharmaceuticals	3.8832 of 5 stars	$20.35 +0.2%	$21.00 +3.2%	+96.8%	$6.48B	$3.12B	41.53	8,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIP) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, LNTH, AMRX, and BLTE

How does ANI Pharmaceuticals compare to ADMA Biologics?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Summary

How does ANI Pharmaceuticals compare to Lantheus?

Summary

How does ANI Pharmaceuticals compare to Amneal Pharmaceuticals?

Summary

How does ANI Pharmaceuticals compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ANI Pharmaceuticals (ANIP) Competitors

ANIP vs. ADMA, ANVS, LNTH, AMRX, and BLTE

How does ANI Pharmaceuticals compare to ADMA Biologics?

Is ADMA or ANIP more profitable?

Do analysts prefer ADMA or ANIP?

Do institutionals & insiders hold more shares of ADMA or ANIP?

Which has more volatility and risk, ADMA or ANIP?

Does the media favor ADMA or ANIP?

Which has higher earnings & valuation, ADMA or ANIP?

Summary

How does ANI Pharmaceuticals compare to Annovis Bio?

Which has preferable valuation & earnings, ANVS or ANIP?

Does the media favor ANVS or ANIP?

Do analysts prefer ANVS or ANIP?

Which has more volatility & risk, ANVS or ANIP?

Do institutionals and insiders hold more shares of ANVS or ANIP?

Is ANVS or ANIP more profitable?

Summary

How does ANI Pharmaceuticals compare to Lantheus?

Does the media prefer ANIP or LNTH?

Which has more risk & volatility, ANIP or LNTH?

Do analysts recommend ANIP or LNTH?

Is ANIP or LNTH more profitable?

Which has preferable valuation & earnings, ANIP or LNTH?

Do insiders and institutionals believe in ANIP or LNTH?

Summary

How does ANI Pharmaceuticals compare to Amneal Pharmaceuticals?

Which has better valuation and earnings, AMRX or ANIP?

Does the media favor AMRX or ANIP?

Which has more volatility and risk, AMRX or ANIP?

Do analysts rate AMRX or ANIP?

Do insiders & institutionals hold more shares of AMRX or ANIP?

Is AMRX or ANIP more profitable?

Summary

How does ANI Pharmaceuticals compare to Belite Bio?

Do insiders and institutionals hold more shares of BLTE or ANIP?

Which has more volatility & risk, BLTE or ANIP?

Which has higher earnings & valuation, BLTE or ANIP?

Is BLTE or ANIP more profitable?

Does the media favor BLTE or ANIP?

Do analysts rate BLTE or ANIP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP vs. The Competition

ANI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools